[go: up one dir, main page]

MX2019014302A - Agente para prevenir o tratar la ataxia espinocerebelosa. - Google Patents

Agente para prevenir o tratar la ataxia espinocerebelosa.

Info

Publication number
MX2019014302A
MX2019014302A MX2019014302A MX2019014302A MX2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A MX 2019014302 A MX2019014302 A MX 2019014302A
Authority
MX
Mexico
Prior art keywords
prevent
treat
ataxia
agent
spinocerebellous
Prior art date
Application number
MX2019014302A
Other languages
English (en)
Other versions
MX393700B (es
Inventor
Tomohiro Okuda
Hiroshi Kobayashi
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2019014302A publication Critical patent/MX2019014302A/es
Publication of MX393700B publication Critical patent/MX393700B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige al problema de proporcionar un agente terapéutico o profiláctico superior para la ataxia espinocerebelosa. El 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azet idin-3-ol o una sal del mismo tiene un efecto de supresión de la atrofia cerebral, en particular, la atrofia cerebelosa, y por consiguiente es útil como un agente terapéutico o profiláctico para la ataxia espinocerebelosa. Por lo tanto, es posible prevenir o tratar la atrofia cerebelosa observada en la ataxia espinocerebelosa por medio de la administración del 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo.
MX2019014302A 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa. MX393700B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145101 2017-07-27
PCT/JP2018/021224 WO2018221730A1 (ja) 2017-06-02 2018-06-01 脊髄小脳変性症予防または治療剤

Publications (2)

Publication Number Publication Date
MX2019014302A true MX2019014302A (es) 2022-07-05
MX393700B MX393700B (es) 2025-03-24

Family

ID=64454849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014302A MX393700B (es) 2017-06-02 2018-06-01 Agente para prevenir o tratar la ataxia espinocerebelosa.

Country Status (15)

Country Link
US (1) US11660287B2 (es)
EP (1) EP3632430A4 (es)
JP (1) JP7133547B2 (es)
KR (1) KR20190138696A (es)
CN (1) CN110691593B (es)
AU (1) AU2018277981B2 (es)
BR (1) BR112019024881A2 (es)
CA (1) CA3067455C (es)
IL (1) IL270910B2 (es)
MX (1) MX393700B (es)
NZ (1) NZ759647A (es)
RU (1) RU2728717C1 (es)
SG (1) SG11201911515QA (es)
WO (1) WO2018221730A1 (es)
ZA (1) ZA201907974B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632431A4 (en) 2017-06-02 2020-06-03 FUJIFILM Toyama Chemical Co., Ltd. AGENTS FOR PREVENTING OR TREATING BRAIN ATROPHY
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
EP3632429A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR REDUCING AMYLOID PROTEIN CONTENT
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753656A (en) * 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
AU9130498A (en) 1997-09-05 1999-03-22 Human Genome Sciences, Inc. 50 human secreted proteins
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
PL217872B1 (pl) 2001-10-19 2014-08-29 Toyama Chemical Co Ltd Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól
JP4675103B2 (ja) 2002-06-14 2011-04-20 富山化学工業株式会社 脳機能を改善する医薬組成物および脳機能を改善するための方法
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
TWI350754B (en) * 2004-09-09 2011-10-21 Shionogi & Co A pharmaceutical composition for treating spinocerebellar ataxia
JP5196641B2 (ja) * 2004-09-09 2013-05-15 塩野義製薬株式会社 脊髄小脳変性症治療剤
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
AU2007244409B2 (en) 2006-04-26 2011-12-01 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
PL2265578T3 (pl) 2008-03-04 2015-12-31 Vernalis R&D Ltd Pochodne azetydyny
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
RU2625767C2 (ru) 2012-02-22 2017-07-18 Тояма Кемикал Ко., Лтд. Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2014053409A1 (en) 2012-10-01 2014-04-10 F. Hoffmann-La Roche Ag Benzimidazol.es as cns active agents
CA2938184C (en) 2014-01-31 2021-11-23 Takuya Takahashi Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
JP6165323B2 (ja) 2014-04-25 2017-07-19 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
DK3253762T3 (da) 2015-02-02 2021-07-19 UCB Biopharma SRL 9h-pyrrolo-dipyridinderivater.
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
WO2017111005A1 (ja) * 2015-12-25 2017-06-29 富山化学工業株式会社 １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含む錠剤
EP3632431A4 (en) 2017-06-02 2020-06-03 FUJIFILM Toyama Chemical Co., Ltd. AGENTS FOR PREVENTING OR TREATING BRAIN ATROPHY
EP3632429A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR REDUCING AMYLOID PROTEIN CONTENT
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
RU2739199C1 (ru) 2017-06-02 2020-12-21 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Лекарственное средство для предотврашения или лечения таупатии
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
CA3067455A1 (en) 2018-12-06
KR20190138696A (ko) 2019-12-13
US20200085787A1 (en) 2020-03-19
JP7133547B2 (ja) 2022-09-08
AU2018277981A1 (en) 2019-12-19
RU2728717C1 (ru) 2020-07-30
ZA201907974B (en) 2022-03-30
EP3632430A4 (en) 2020-06-10
IL270910B2 (en) 2024-03-01
CA3067455C (en) 2021-11-23
NZ759647A (en) 2022-02-25
EP3632430A1 (en) 2020-04-08
US11660287B2 (en) 2023-05-30
BR112019024881A2 (pt) 2020-06-16
CN110691593B (zh) 2023-05-02
WO2018221730A1 (ja) 2018-12-06
MX393700B (es) 2025-03-24
CN110691593A (zh) 2020-01-14
SG11201911515QA (en) 2020-01-30
IL270910B1 (en) 2023-11-01
JPWO2018221730A1 (ja) 2020-04-09
AU2018277981B2 (en) 2021-04-08
IL270910A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
ECSP13013035A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida
EA201892505A1 (ru) Амидозамещенные производные пиридинилтриазола и их применение
MX2019014041A (es) Inhibidores pirazolicos de magl.
MX2019014302A (es) Agente para prevenir o tratar la ataxia espinocerebelosa.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
JOP20200252B1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
MX2019014310A (es) Agente para prevenir o tratar atrofia cerebral.
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
MX394436B (es) Agente para prevenir o tratar la tauopatia.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.